Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 60 | 2024 | 15694 | 2.910 |
Why?
|
| Triple Negative Breast Neoplasms | 21 | 2024 | 1215 | 2.670 |
Why?
|
| Breast Diseases | 8 | 2024 | 201 | 2.000 |
Why?
|
| Mammography | 28 | 2023 | 1010 | 1.990 |
Why?
|
| Neoadjuvant Therapy | 29 | 2024 | 4975 | 1.670 |
Why?
|
| Breast | 16 | 2023 | 1344 | 1.510 |
Why?
|
| Calcinosis | 7 | 2021 | 423 | 1.400 |
Why?
|
| Ultrasonography, Mammary | 12 | 2022 | 380 | 1.400 |
Why?
|
| Image-Guided Biopsy | 11 | 2022 | 327 | 1.230 |
Why?
|
| Biopsy | 6 | 2022 | 3443 | 0.940 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2024 | 7702 | 0.880 |
Why?
|
| Multimodal Imaging | 7 | 2022 | 550 | 0.860 |
Why?
|
| Mastectomy, Segmental | 5 | 2021 | 1026 | 0.810 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2019 | 674 | 0.760 |
Why?
|
| Breast Implants | 3 | 2022 | 391 | 0.580 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2018 | 1216 | 0.580 |
Why?
|
| Molecular Imaging | 1 | 2018 | 185 | 0.560 |
Why?
|
| Female | 70 | 2024 | 141928 | 0.520 |
Why?
|
| Mastectomy | 7 | 2024 | 1534 | 0.490 |
Why?
|
| Ultrasonography | 7 | 2023 | 1863 | 0.450 |
Why?
|
| Mammaplasty | 2 | 2022 | 780 | 0.420 |
Why?
|
| Stereotaxic Techniques | 3 | 2019 | 172 | 0.420 |
Why?
|
| Humans | 75 | 2024 | 261506 | 0.390 |
Why?
|
| Carcinoma, Papillary | 2 | 2018 | 584 | 0.390 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 611 | 0.380 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 387 | 0.360 |
Why?
|
| Radiographic Image Enhancement | 4 | 2014 | 402 | 0.350 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 1656 | 0.350 |
Why?
|
| Angiomatosis | 2 | 2021 | 26 | 0.330 |
Why?
|
| Retrospective Studies | 21 | 2024 | 37905 | 0.330 |
Why?
|
| Neoplasm Staging | 12 | 2023 | 13658 | 0.310 |
Why?
|
| Lymph Nodes | 5 | 2023 | 2967 | 0.300 |
Why?
|
| Middle Aged | 31 | 2023 | 86204 | 0.290 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 1162 | 0.280 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2017 | 134 | 0.280 |
Why?
|
| Aged | 23 | 2023 | 70117 | 0.250 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 895 | 0.250 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 429 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 15862 | 0.240 |
Why?
|
| Nipples | 1 | 2024 | 132 | 0.230 |
Why?
|
| Mass Screening | 4 | 2013 | 1509 | 0.220 |
Why?
|
| Anthracyclines | 2 | 2023 | 331 | 0.220 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 1363 | 0.220 |
Why?
|
| Adult | 23 | 2021 | 77950 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2013 | 1226 | 0.210 |
Why?
|
| Electrons | 1 | 2023 | 168 | 0.210 |
Why?
|
| Prospective Studies | 12 | 2023 | 12873 | 0.200 |
Why?
|
| Phthalazines | 2 | 2022 | 253 | 0.200 |
Why?
|
| Contrast Media | 5 | 2022 | 1472 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 10035 | 0.200 |
Why?
|
| Sensitivity and Specificity | 9 | 2018 | 4971 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5437 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2015 | 925 | 0.190 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2022 | 341 | 0.190 |
Why?
|
| Fasciitis | 1 | 2020 | 35 | 0.190 |
Why?
|
| Esthetics | 1 | 2021 | 189 | 0.180 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 191 | 0.180 |
Why?
|
| Tumor Burden | 3 | 2021 | 1987 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2015 | 5542 | 0.180 |
Why?
|
| Axilla | 5 | 2023 | 902 | 0.180 |
Why?
|
| Margins of Excision | 1 | 2021 | 285 | 0.170 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 6009 | 0.170 |
Why?
|
| Positron-Emission Tomography | 3 | 2013 | 2173 | 0.170 |
Why?
|
| Hyperplasia | 2 | 2021 | 557 | 0.170 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 1959 | 0.170 |
Why?
|
| Protons | 1 | 2021 | 473 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2022 | 1529 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2022 | 3890 | 0.160 |
Why?
|
| Fat Necrosis | 1 | 2018 | 63 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2019 | 129 | 0.160 |
Why?
|
| Phyllodes Tumor | 1 | 2018 | 62 | 0.150 |
Why?
|
| Taxoids | 1 | 2021 | 967 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 14889 | 0.140 |
Why?
|
| Radiopharmaceuticals | 4 | 2023 | 1301 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2017 | 96 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2024 | 32848 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2015 | 73 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2016 | 333 | 0.120 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 14289 | 0.120 |
Why?
|
| Image Enhancement | 2 | 2015 | 561 | 0.120 |
Why?
|
| Mobile Health Units | 1 | 2013 | 34 | 0.120 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 10331 | 0.110 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 878 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 882 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2020 | 1415 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3251 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 992 | 0.110 |
Why?
|
| Genomics | 1 | 2023 | 2738 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 4744 | 0.100 |
Why?
|
| Prognosis | 7 | 2021 | 21713 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2013 | 445 | 0.100 |
Why?
|
| Lymphatic Metastasis | 5 | 2023 | 4844 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 592 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 4367 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 361 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3981 | 0.090 |
Why?
|
| Proteome | 1 | 2014 | 561 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2022 | 2803 | 0.090 |
Why?
|
| Sarcoma | 1 | 2020 | 1725 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 864 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2015 | 927 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 999 | 0.080 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 509 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 3719 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 2518 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 479 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7551 | 0.070 |
Why?
|
| Time Factors | 2 | 2017 | 12926 | 0.070 |
Why?
|
| Precancerous Conditions | 2 | 2011 | 1058 | 0.070 |
Why?
|
| Rituximab | 1 | 2011 | 1528 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 21445 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2023 | 1996 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2086 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 1046 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 1271 | 0.070 |
Why?
|
| Cytarabine | 1 | 2011 | 1973 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 1299 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 29902 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 690 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2021 | 833 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 1678 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 2292 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 2864 | 0.050 |
Why?
|
| Rupture | 1 | 2022 | 61 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 521 | 0.050 |
Why?
|
| Amides | 1 | 2021 | 123 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2022 | 660 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 429 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 206 | 0.050 |
Why?
|
| Metaplasia | 1 | 2022 | 383 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2022 | 1062 | 0.050 |
Why?
|
| Biological Transport | 1 | 2021 | 597 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2022 | 671 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 580 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 358 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 2017 | 66 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 493 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 1546 | 0.030 |
Why?
|
| Risk Factors | 3 | 2018 | 17523 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1048 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 275 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1022 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 3001 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2022 | 3005 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.030 |
Why?
|
| Data Display | 1 | 2013 | 49 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2013 | 62 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 1258 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 98 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4892 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1742 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 164 | 0.030 |
Why?
|
| Workload | 1 | 2013 | 198 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 700 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 694 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5047 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 671 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 690 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 1099 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 945 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1323 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7548 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4298 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 4938 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 5673 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8873 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9180 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5687 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 31252 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.010 |
Why?
|
| Male | 2 | 2018 | 123000 | 0.010 |
Why?
|